Statement: A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 13/72 (18.06%)   Neutrophils/granulocytes * 24/72 (5.56%)   Mucositis/stomatitis * 22/72 (2.78%)   Vomiting * 21/72 (1.39%)   Febrile neutropaenia * 6/72 (8.33%)   Infection with normal absolute neutrophil count (ANC) or grade 1 or 2 neutrophils * 21/72 (1.39%)
Secondary_evidence: Adverse Events 1:   Total: 52/133 (39.10%)   Thrombocytopenia 2/133 (1.50%)   Anaemia 1/133 (0.75%)   Disseminated intravascular coagulation 0/133 (0.00%)   Atrial thrombosis 1/133 (0.75%)   Cardiac failure 0/133 (0.00%)   Vertigo 0/133 (0.00%)   Vomiting 3/133 (2.26%)   Nausea 1/133 (0.75%)   Colitis 1/133 (0.75%)   Constipation 1/133 (0.75%)   Enteritis 0/133 (0.00%)   Abdominal pain 0/133 (0.00%) Adverse Events 2:   Total: 16/67 (23.88%)   Thrombocytopenia 0/67 (0.00%)   Anaemia 0/67 (0.00%)   Disseminated intravascular coagulation 1/67 (1.49%)   Atrial thrombosis 0/67 (0.00%)   Cardiac failure 1/67 (1.49%)   Vertigo 1/67 (1.49%)   Vomiting 0/67 (0.00%)   Nausea 1/67 (1.49%)   Colitis 0/67 (0.00%)   Constipation 0/67 (0.00%)   Enteritis 1/67 (1.49%)   Abdominal pain 2/67 (2.99%)